BRAF and lung carcinoma: Since the first generation of BRAFV600E inhibitors is usually only weakly active against non-V600 BRAF-mutant cancers, compounds targeting BRAF-mutant dimers were developed (e.g., PLX8394 and lifirafenib), which showed promising activities against non-V600 BRAF-mutant lung cancers resistant to vemurafenib[34,35].